Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome

NCT07000383 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Diarrhea-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome of Diarrhea Type (IBS-D)

Interventions

DEVICE: Gelsectan
DRUG: Antispasmodic Agent

Sponsor

University Medical Center Ho Chi Minh City (UMC)